GlassScriptPhysician profile
Alejandro Trepp Carrasco
NPI 1144518085
$12,559.23
in general payments reported to CMS, 2019-2025
49 companies · $457 in 2025
The $457 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $1,193 · 2021: $3,256 · 2022: $3,722 · 2023: $1,600 · 2024: $262 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,996.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,494.92 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Sanofi-Aventis U.S. LLC | $1,358.96 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $879.81 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $748.43 | 2019-2023 | Farxiga |
| Mannkind Corporation | $711.63 | 2019-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $693.00 | 2019-2023 | Jardiance, Trijardy Xr, Tradjenta |
| Amgen INC. | $416.05 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $386.82 | 2019-2023 | Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $325.18 | 2021-2023 | |
| Abbott Laboratories | $299.66 | 2020-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $217.45 | 2020-2023 | Korlym |
| Merck Sharp & Dohme LLC | $213.44 | 2019-2021 | |
| Radius Health, INC. | $186.63 | 2021-2023 | Tymlos |
| Amneal Pharmaceuticals LLC | $181.76 | 2019-2023 | Unithroid |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Trepp Carrasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.